EV Biologics Chief Medical Officer Publication on COVID-19 & Exosomes
EV Biologics Corp, trading under OTC Pink:YECO, has provided an update on a publication by Chief Medical Officer Dr. Jason Sanders, discussing the role of small extracellular vesicles (EVs) in COVID-19 treatment. The review highlights therapeutic potentials of mesenchymal stem cell (MSC) exosomes for Acute Lung Injury (ALI). Dr. Sanders emphasizes ongoing advancements in EV-based therapeutics. The company is focused on developing optimized clonal stem cell lines for FDA-approved biomanufactured drugs targeting various clinical conditions, including autoimmune and degenerative diseases.
- Development of MSC exosomes as potential treatments for COVID-19 and other conditions.
- Focus on FDA approval for a variety of clinical indications, showcasing market potential.
- Advanced technological approach to biopharmaceuticals that may yield superior therapeutic options.
- No specific financial metrics or timelines provided for product development.
- Possible reliance on external factors for clinical trial success, introducing risk.
NASHVILLE, TN / ACCESSWIRE / October 28, 2021 / EV Biologics Corp, OTC Pink:YECO, today updated shareholders about a recent publication authored by its Chief Medical Officer, Dr. Jason Sanders.
This review discusses some of the cellular and molecular pathology of COVID-19 and the relevant therapeutic mechanisms of small extracellular vesicles (EVs), such as exosomes, in Acute Lung Injury (ALI). The original manuscript was initially prepared by Dr. Sanders in March 2020, near the beginning of the pandemic, to illustrate the therapeutic potential of mesenchymal stem cell (MSC) exosomes in this type of disease. Since that time, a number of clinical trials investigating MSC exosomes as a therapy for COVID-19 have been initiated.
Please download the article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225928/.
CMO Dr. Jason Sanders said: "This publication presents only a very small fraction of the potential of EV-based therapeutics produced by MSCs and other stem cells. Through convergence of multiple revolutionary technologies, we are advancing our objectives to capture the remarkable therapeutic potential of MSCs, to optimize it for a breadth of focused clinical applications, and to standardize the products and processes for preparation of next-generation therapeutics."
EV Biologics is developing optimized clonal stem cell lines for biomanufacturing of naïve and engineered EV-based therapeutics that will be developed into biological drugs seeking FDA approval for several different clinical indications: acute lung injury (eg. COVID-19, influenza, acute respiratory distress syndrome), autoimmune (lupus, multiple sclerosis, rheumatoid arthritis, etc) and systemic inflammatory syndromes, osteoarthritis and other degenerative musculoskeletal disease, neurodegenerative conditions, metabolic diseases, and other age-related conditions.
CEO Daniel Mckinney, said "EV Biologics has adopted a very advanced technological approach to biopharmaceutical development that will rapidly develop and efficiently manufacture EV-based therapeutics within a rigorous cGMP framework to prepare investigational new drugs, far superior to anything currently on the market, for submission to FDA. Our audacious goal is to conquer incurable diseases and revolutionize modern medicine to deliver better health for patients worldwide."
About the Company
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on developing and enhancing the intrinsic therapeutic activity of mesenchymal stromal cell (MSC) secreted factors, as well as targeted delivery of bioactive molecules using engineered exosomes. The company is working to optimize cell lines for production of native bioactive nanoparticles and to establish an exosome engineering platform to enhance specific therapeutic activity. Initially, these novel regenerative products will be produced for preclinical research on a number of clinical indications. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in these
bioengineered products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.
Forward-Looking Statements
This news release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
YECO has 7.22 million shares issued and outstanding with a float of 1,016,375 shares.
Contact:
Dennis Burns
Investor Relations
Tel(567)237-4132
dburns@nvestrain.com
For more information on EV Biologics please visit: www.evbiologics.com
SOURCE: EV Biologics Corp,
View source version on accesswire.com:
https://www.accesswire.com/670115/EV-Biologics-Chief-Medical-Officer-Publication-on-COVID-19-Exosomes
FAQ
What recent publication did EV Biologics release regarding COVID-19?
What is the focus of EV Biologics' research?
What is the stock symbol for EV Biologics?
How many shares are issued and outstanding for YECO?
What are the potential applications of EV Biologics' therapeutics?
